Session of 2023

HOUSE BILL No. 2398

By Committee on Corrections and Juvenile Justice

2-10

AN ACT concerning crimes, punishment and criminal procedure; relating to crimes involving controlled substances; adding the placing of controlled substances into pills into the definition of manufacture; excluding materials used to detect the presence of fentanyl, ketamine or gamma hydroxybutyric acid from the definition of drug paraphernalia; increasing the criminal penalties for manufacturing fentanyl-related controlled substance; creating a special sentencing rule for distributing fentanyl-related controlled substance; amending K.S.A. 2022 Supp. 21-5701, 21-5703 and 21-6805 and repealing the existing sections; also repealing K.S.A. 2022 Supp. 21-5701b.

1 2

Be it enacted by the Legislature of the State of Kansas:

Section 1. K.S.A. 2022 Supp. 21-5701 is hereby amended to read as follows: 21-5701. As used in K.S.A. 2022 Supp. 21-5701 through 21-5717, and amendments thereto:

- (a) "Controlled substance" means any drug, substance or immediate precursor included in any of the schedules designated in K.S.A. 65-4105, 65-4107, 65-4109, 65-4111 and 65-4113, and amendments thereto.
- (b) (1) "Controlled substance analog" means a substance that is intended for human consumption, and at least one of the following:
- (A) The chemical structure of the substance is substantially similar to the chemical structure of a controlled substance listed in or added to the schedules designated in K.S.A. 65-4105 or 65-4107, and amendments thereto;
- (B) the substance has a stimulant, depressant or hallucinogenic effect on the central nervous system substantially similar to the stimulant, depressant or hallucinogenic effect on the central nervous system of a controlled substance included in the schedules designated in K.S.A. 65-4105 or 65-4107, and amendments thereto; or
- (C) with respect to a particular individual, such individual represents or intends the substance to have a stimulant, depressant or hallucinogenic effect on the central nervous system substantially similar to the stimulant, depressant or hallucinogenic effect on the central nervous system of a controlled substance included in the schedules designated in K.S.A. 65-4105 or 65-4107, and amendments thereto.

- (2) "Controlled substance analog" does not include:
- (A) A controlled substance;
- (B) a substance for which there is an approved new drug application; or
- (C) a substance with respect to which an exemption is in effect for investigational use by a particular person under section 505 of the federal food, drug, and cosmetic act, 21 U.S.C. § 355, to the extent conduct with respect to the substance is permitted by the exemption.
- (c) "Cultivate" means the planting or promotion of growth of five or more plants that contain or can produce controlled substances.
- (d) "Distribute" means the actual, constructive or attempted transfer from one person to another of some item whether or not there is an agency relationship. "Distribute" includes, but is not limited to, sale, offer for sale or any act that causes some item to be transferred from one person to another. "Distribute" does not include acts of administering, dispensing or prescribing a controlled substance as authorized by the pharmacy act of the state of Kansas, the uniform controlled substances act or otherwise authorized by law.
 - (e) (1) "Drug" means:
- (A) Substances recognized as drugs in the official United States pharmacopeia, official homeopathic pharmacopoeia of the United States or official national formulary or any supplement to any of them;
- (B) substances intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease in humans or animals;
- (C) substances, other than food, intended to affect the structure or any function of the body of humans or animals; and
- (D) substances intended for use as a component of any article specified in subparagraph (A), (B) or (C).
- (2) "Drug" does not include devices or their components, parts or accessories.
- (f) (1) "Drug paraphernalia" means all equipment and materials of any kind that are used, or primarily intended or designed for use in planting, propagating, cultivating, growing, harvesting, manufacturing, compounding, converting, producing, processing, preparing, testing, analyzing, packaging, repackaging, storing, containing, concealing, injecting, ingesting, inhaling or otherwise introducing into the human body a controlled substance and in violation of this act.
 - (2) "Drug paraphernalia" shall include includes, but is not limited to:
- (1)(A) Kits used or intended for use in planting, propagating, cultivating, growing or harvesting any species of plant that is a controlled substance or from which a controlled substance can be derived;
- (2)(B) kits used or intended for use in manufacturing, compounding, converting, producing, processing or preparing controlled substances;

- $\frac{3}{C}$ isomerization devices used or intended for use in increasing the potency of any species of plant that is a controlled substance;
- (4)(D) testing equipment used or intended for use in identifying or in analyzing the strength, effectiveness or purity of controlled substances;
- (5)(E) scales and balances used or intended for use in weighing or measuring controlled substances;
- (6)(F) diluents and adulterants, including, but not limited to, quinine hydrochloride, mannitol, mannite, dextrose and lactose that are used or intended for use in cutting controlled substances;
- (7)(G) separation gins and sifters used or intended for use in removing twigs and seeds from or otherwise cleaning or refining marijuana;
- (8)(H) blenders, bowls, containers, spoons and mixing devices used or intended for use in compounding controlled substances;
- (9)(1) capsules, balloons, envelopes, bags and other containers used or intended for use in packaging small quantities of controlled substances;
- $\frac{(10)}{J}$ containers and other objects used or intended for use in storing or concealing controlled substances;
- $\frac{(11)}{K}$ hypodermic syringes, needles and other objects used or intended for use in parenterally injecting controlled substances into the human body;
- $\frac{(12)}{L}$ objects used or primarily intended or designed for use in ingesting, inhaling or otherwise introducing marijuana, cocaine, hashish, hashish oil, phencyclidine (PCP), methamphetamine or amphetamine into the human body, such as:
- (A)(i) Metal, wooden, acrylic, glass, stone, plastic or ceramic pipes with or without screens, permanent screens, hashish heads or punctured metal bowls;
- (B)(ii) water pipes, bongs or smoking pipes designed to draw smoke through water or another cooling device;
- (C)(iii) carburetion pipes, glass or other—heat resistant heat-resistant tubes or any other device used, intended to be used or designed to be used to cause vaporization of a controlled substance for inhalation;
 - (D)(iv) smoking and carburetion masks;
- 35 (E)(v) roach clips, objects used to hold burning material, such as a marijuana cigarette, that has become too small or too short to be held in the hand;
 - (F)(vi) miniature cocaine spoons and cocaine vials;
- 39 (G)(vii) chamber smoking pipes;
- 40 (H)(viii) carburetor smoking pipes;
- $\frac{\text{(I)}(ix)}{\text{electric smoking pipes;}}$
- (J)(x) air-driven smoking pipes;
- $\frac{K}{(K)}(xi)$ chillums;

(L)(xii) bongs;

(M)(xiii) ice pipes or chillers;

- $\frac{(N)}{(xiv)}$ any smoking pipe manufactured to disguise its intended purpose;
 - $(\Theta)(xv)$ wired cigarette papers; or
 - (P)(xvi) cocaine freebase kits.
 - (2)(3) "Drug paraphernalia" shall does not include:
- (A) Any products, chemicals or materials described in K.S.A. 2022 Supp. 21-5709(a), and amendments thereto; or
- (B) any materials used or intended for use to test a substance for the presence of fentanyl, a fentanyl analog, ketamine or gamma hydroxybutyric acid.
- (g) "Fentanyl-related controlled substance" means any substance designated in K.S.A. 65-4105(b)(1), (b)(2), (b)(4), (b)(10), (b)(11), (b)(11), (b)(14), (b)(15), (b)(16), (b)(20), (b)(22), (b)(23), (b)(24), (b)(37), (b)(41), (b)(45), (b)(46), (b)(47), (b)(49), (b)(57), (b)(58), (b)(59), (b)(60), (b)(61), (b)(62), (b)(73), (b)(74), (b)(78), (g)(1) or (g)(2) or 65-4107(c)(1), (c)(6), (c)(9), (c)(26), (c)(28), (c)(30), (f)(3)(A) or (f)(3)(B), and amendments thereto, or any analog thereof.
- (h) "Immediate precursor" means a substance that the state board of pharmacy has found to be and by rules and regulations designates as being the principal compound commonly used or produced primarily for use and that is an immediate chemical intermediary used or likely to be used in the manufacture of a controlled substance, the control of which is necessary to prevent, curtail or limit manufacture.
 - (h)(i) "Isomer" means all enantiomers and diastereomers.
- (i)(j) "Manufacture" means the production, preparation, propagation, compounding, conversion or processing of *or placing into pill or capsule form* a controlled substance either directly or indirectly or by extraction from substances of natural origin or independently by means of chemical synthesis or by a combination of extraction and chemical synthesis. "Manufacture" does not include:
- (1) The preparation or compounding of a controlled substance by an individual for the individual's own lawful use or the preparation, compounding, packaging or labeling of a controlled substance:
- (A) By a practitioner or the practitioner's agent pursuant to a lawful order of a practitioner as an incident to the practitioner's administering or dispensing of a controlled substance in the course of the practitioner's professional practice; or
- (B) by a practitioner or by the practitioner's authorized agent under such practitioner's supervision for the purpose of or as an incident to research, teaching or chemical analysis or by a pharmacist or medical care facility as an incident to dispensing of a controlled substance; or

- (2) the addition of diluents or adulterants, including, but not limited to, quinine hydrochloride, mannitol, mannite, dextrose or lactose that are intended for use in cutting a controlled substance.
- $\frac{(j)}{k}$ "Marijuana" means all parts of all varieties of the plant Cannabis whether growing or not, the seeds thereof, the resin extracted from any part of the plant and every compound, manufacture, salt, derivative, mixture or preparation of the plant, its seeds or resin. "Marijuana" does not include:
- (1) The mature stalks of the plant, fiber produced from the stalks, oil or cake made from the seeds of the plant, any other compound, manufacture, salt, derivative, mixture or preparation of the mature stalks, except the resin extracted therefrom, fiber, oil or cake or the sterilized seed of the plant that is incapable of germination;
- (2) any substance listed in schedules II through V of the uniform controlled substances act;
- (3) drug products approved by the United States food and drug administration as of the effective date of this act;
- (4) cannabidiol (other trade name: 2-[(3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol); or
- (5) industrial hemp as defined in K.S.A. 2-3901, and amendments thereto, when cultivated, produced, possessed or used for activities authorized by the commercial industrial hemp act.
 - (k)(l) "Minor" means a person under 18 years of age.
- (+) (m) "Narcotic drug" means any of the following whether produced directly or indirectly by extraction from substances of vegetable origin or independently by means of chemical synthesis or by a combination of extraction and chemical synthesis:
- (1) Opium and opiate and any salt, compound, derivative or preparation of opium or opiate;
- (2) any salt, compound, isomer, derivative or preparation thereof that is chemically equivalent or identical with any of the substances referred to in paragraph (1) but not including the isoquinoline alkaloids of opium;
 - (3) opium poppy and poppy straw;
- (4) coca leaves and any salt, compound, derivative or preparation of coca leaves and any salt, compound, isomer, derivative or preparation thereof that is chemically equivalent or identical with any of these substances, but not including decocainized coca leaves or extractions of coca leaves that do not contain cocaine or ecgonine.
- (m)(n) "Opiate" means any substance having an addiction-forming or addiction-sustaining liability similar to morphine or being capable of conversion into a drug having addiction-forming or addiction-sustaining liability. "Opiate" does not include, unless specifically designated as controlled under K.S.A. 65-4102, and amendments thereto, the

dextrorotatory isomer of 3-methoxy-n-methylmorphinan and its salts (dextromethorphan). "Opiate" does include its racemic and levorotatory forms.


- (n)(o) "Opium poppy" means the plant of the species Papaver somniferum l. except its seeds.
- (o)(p) "Person" means an individual, corporation, government or governmental subdivision or agency, business trust, estate, trust, partnership, association or any other legal entity.
- $\frac{(p)}{(q)}$ "Poppy straw" means all parts, except the seeds, of the opium poppy, after mowing.
- (q) "Possession" means having joint or exclusive control over an item with knowledge of and intent to have such control or knowingly keeping some item in a place where the person has some measure of access and right of control.
- (r) "School property" means property upon which is located a structure used by a unified school district or an accredited nonpublic school for student instruction or attendance or extracurricular activities of pupils enrolled in kindergarten or any of the grades one through 12. This definition shall not be construed as requiring that school be in session or that classes are actually being held at the time of the offense or that children must be present within the structure or on the property during the time of any alleged criminal act. If the structure or property meets the above definition, the actual use of that structure or property at the time alleged shall not be a defense to the crime charged or the sentence imposed.
- (s) "Simulated controlled substance" means any product that identifies itself by a common name or slang term associated with a controlled substance and that indicates on its label or accompanying promotional material that the product simulates the effect of a controlled substance.
- Sec. 2. K.S.A. 2022 Supp. 21-5703 is hereby amended to read as follows: 21-5703. (a) It shall be unlawful for any person to manufacture any controlled substance or controlled substance analog.
 - (b) Violation or attempted violation of subsection (a) is a:
- (1) Drug severity level 2 felony, except as provided in subsections (b) (2) and (b)(3);
 - (2) drug severity level 1 felony if:
- (A) The controlled substance is not methamphetamine, as defined by subsection (d)(3) or (f)(1) of K.S.A. 65-4107(d)(3) or (f)(1), and amendments thereto, or an analog thereof; and
- 41 (B) the controlled substance is not a fentanyl-related controlled 42 substance; and
 - (C) the offender has a prior conviction for unlawful manufacturing of

a controlled substance under this section, K.S.A. 65-4159, prior to its repeal, K.S.A. 2010 Supp. 21-36a03, prior to its transfer, or a substantially similar offense from another jurisdiction and the substance was not methamphetamine, as defined by subsection (d)(3) or (f)(1) of K.S.A. 65-4107(d)(3) or (f)(1), and amendments thereto, or an analog thereof, in any such prior conviction; and

- (3) drug severity level 1 felony if the controlled substance is methamphetamine, as defined by subsection (d)(3) or (f)(1) of K.S.A. 65-4107(d)(3) or (f)(1), and amendments thereto, or an analog thereof, or is a fentanyl-related controlled substance.
- (c) The provisions of subsection (d) of K.S.A. 2022 Supp. 21-5301(d), and amendments thereto, shall not apply to a violation of attempting to unlawfully manufacture any controlled substance or controlled substance analog pursuant to this section.
- (d) For persons arrested and charged under this section, bail shall be at least \$50,000 cash or surety, and such person shall not be released upon the person's own recognizance pursuant to K.S.A. 22-2802, and amendments thereto, unless the court determines, on the record, that the defendant is not likely to re-offend, the court imposes pretrial supervision, or the defendant agrees to participate in a licensed or certified drug treatment program.
- (e) The sentence of a person who violates this section shall not be subject to statutory provisions for suspended sentence, community service work or probation.
- (f) The sentence of a person who violates this section, K.S.A. 65-4159, prior to its repeal or K.S.A. 2010 Supp. 21-36a03, prior to its transfer, shall not be reduced because these sections prohibit conduct identical to that prohibited by K.S.A. 65-4161 or 65-4163, prior to their repeal, K.S.A. 2010 Supp. 21-36a05, prior to its transfer, or K.S.A. 2022 Supp. 21-5705, and amendments thereto.
- Sec. 3. K.S.A. 2022 Supp. 21-6805 is hereby amended to read as follows: 21-6805. (a) The provisions of this section shall be applicable to the sentencing guidelines grid for drug crimes. The following sentencing guidelines grid for drug crimes shall be applicable to felony crimes under K.S.A. 2022 Supp. 21-5701 through 21-5717, and amendments thereto, except as otherwise provided by law:

SENTENCING RANGE - DRUG OFFENSES

I	1 Misdemeanor No Record	154 146 138	103 98 92	51 49 46		12 11 10
Н	2+ Misdemeanors	161 150 142	108 100 96	54 51 49		14 13 12
Ð	1 Nonperson Felony	162 154 146	110 104 99	57 54 51		16 15 14
Ízu	2 Nonperson Felonies	167 158 150	113 108 101	59 56 52		18 17 16
ഥ	3 + Nonperson Felonies	170 162 154	116 111 105	59 55		22 20 18
D	1 Person Felony	179 170 161	124 117 111	68 64 60	36 34 32	
٥	1 Person & 1 Nonperson Felonies	187 178 169	130 123 117	72 68 65	42 40 37	
В	2 Person Felonies	196 186 176	137 130 122	77 73 68	47 44 41	36 34 32
A	3 + Person Felonies	204 194 185	144 136 130	83 78 74	51 49 46	42 40 37
Category →	Severity Level	I	II	111	IV	Λ



- (b) Sentences expressed in the sentencing guidelines grid for drug crimes in subsection (a) represent months of imprisonment.
- (c) (1) The sentencing court has discretion to sentence at any place within the sentencing range. In the usual case it is recommended that the sentencing judge select the center of the range and reserve the upper and lower limits for aggravating and mitigating factors insufficient to warrant a departure. The sentencing court shall not distinguish between the controlled substances cocaine base (9041L000) and cocaine hydrochloride (9041L005) when sentencing within the sentencing range of the grid block.
- (2) In presumptive imprisonment cases, the sentencing court shall pronounce the complete sentence which shall include the:
 - (A) Prison sentence;

- (B) maximum potential reduction to such sentence as a result of good time; and
- (C) period of postrelease supervision at the sentencing hearing. Failure to pronounce the period of postrelease supervision shall not negate the existence of such period of postrelease supervision.
- (3) In presumptive nonprison cases, the sentencing court shall pronounce the prison sentence as well as the duration of the nonprison sanction at the sentencing hearing.
- (d) Each grid block states the presumptive sentencing range for an offender whose crime of conviction and criminal history place such offender in that grid block. If an offense is classified in a grid block below the dispositional line, the presumptive disposition shall be nonimprisonment. If an offense is classified in a grid block above the dispositional line, the presumptive disposition shall be imprisonment. If an offense is classified in grid blocks 4-E, 4-F, 4-G, 4-H, 4-I, 5-C or 5-D, the court may impose an optional nonprison sentence as provided in subsection (q) of K.S.A. 2022 Supp. 21-6804(q), and amendments thereto.
- (e) The sentence for a second or subsequent conviction for unlawful manufacturing of a controlled substance, K.S.A. 65-4159, prior to its repeal, K.S.A. 2010 Supp. 21-36a03, prior to its transfer, K.S.A. 2022 Supp. 21-5703, and amendments thereto, or a substantially similar offense from another jurisdiction, if the controlled substance in any prior conviction was methamphetamine, as defined by—subsection $\frac{d}{d}$ 00 or $\frac{d}{d}$ 10 or $\frac{d}{d}$ 11 of K.S.A. 65-4107 $\frac{d}{d}$ 21 or $\frac{d}{d}$ 21, and amendments thereto, or an analog thereof, shall be a presumptive term of imprisonment of two times the maximum duration of the presumptive term of imprisonment. The court may impose an optional reduction in

such sentence of not to exceed 50% of the mandatory increase provided by this subsection upon making a finding on the record that one or more of the mitigating factors as specified in K.S.A. 2022 Supp. 21-6815, and amendments thereto, justify such a reduction in sentence. Any decision made by the court regarding the reduction in such sentence shall not be considered a departure and shall not be subject to appeal.

3

5

6 7

8

9

10 11

12 13

14

15

16 17

18

19

20

21

22 23

24

25

26

27

28

29

30

31

32

33

34

35

36 37

38

39

40

41

42

- (f) (1) The sentence for a third or subsequent felony conviction of K.S.A. 65-4160 or 65-4162, prior to their repeal, K.S.A. 2010 Supp. 21-36a06, prior to its transfer, or K.S.A. 2022 Supp. 21-5706, and amendments thereto, shall be a presumptive term of imprisonment and the defendant shall be sentenced to prison as provided by this section. The defendant's term of imprisonment shall be served in the custody of the secretary of corrections in a facility designated by the secretary. Subject to appropriations therefore, the defendant shall participate in an intensive substance abuse treatment program, of at least four months duration, selected by the secretary of corrections. If the secretary determines that substance abuse treatment resources are otherwise available, such term of imprisonment may be served in a facility designated by the secretary of corrections in the custody of the secretary of corrections to participate in an intensive substance abuse treatment program. The secretary's determination regarding the availability of treatment resources shall not be subject to review. Upon the successful completion of such intensive treatment program, the offender shall be returned to the court and the court may modify the sentence by directing that a less severe penalty be imposed in lieu of that originally adjudged. If the offender's term of imprisonment expires, the offender shall be placed under the applicable period of postrelease supervision.
- (2) Such defendant's term of imprisonment shall not be subject to modification under paragraph (1) if:
- (A) The defendant has previously completed a certified drug abuse treatment program, as provided in K.S.A. 75-52,144, and amendments thereto;
- (B) has been discharged or refused to participate in a certified drug abuse treatment program, as provided in K.S.A. 75-52,144, and amendments thereto;
- (C) has completed an intensive substance abuse treatment program under paragraph (1); or
- (D) has been discharged or refused to participate in an intensive substance abuse treatment program under paragraph (1).
- The sentence under this subsection shall not be considered a departure and shall not be subject to appeal.

(g) (1) Except as provided further, if the trier of fact makes a finding that an offender carried a firearm to commit a drug felony, or in furtherance of a drug felony, possessed a firearm, in addition to the sentence imposed pursuant to K.S.A. 2022 Supp. 21-6801 through 21-6824, and amendments thereto, the offender shall be sentenced to:

- (A) Except as provided in subsection (g)(1)(B), an additional 6 months' imprisonment; and
- (B) if the trier of fact makes a finding that the firearm was discharged, an additional 18 months' imprisonment.
- (2) The sentence imposed pursuant to subsection (g)(1) shall be presumptive imprisonment. Such sentence shall not be considered a departure and shall not be subject to appeal.
- (3) The provisions of this subsection shall not apply to violations of K.S.A. 2022 Supp. 21-5706 or 21-5713, and amendments thereto.
- (h) The sentence for a violation of K.S.A. 2022 Supp. 21-5703, and amendments thereto, with respect to material containing any quantity of a fentanyl-related controlled substance shall be presumed imprisonment and shall be two times the maximum duration of the presumptive term of imprisonment. Such sentence shall not be considered a departure and shall not be subject to appeal.
- Sec. 4. K.S.A. 2022 Supp. 21-5701, 21-5701b, 21-5703 and 21-6805 are hereby repealed.
- Sec. 5. This act shall take effect and be in force from and after its publication in the statute book.